ArticleJournal of nanobiotechnology2022
Oral administration of turmeric-derived exosome-like nanovesicles with anti-inflammatory and pro-resolving bioactions for murine colitis therapy.
Article in Journal of nanobiotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 151 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
151 citing papers in PubMed, 241 citations in OpenAlex.
- Extracellular vesicles for next-gen therapeutics and drug delivery.Molecular biomedicine · 2026Review
- Natural Product-Derived Vesicles in Nanotherapeutics.Journal of extracellular vesicles · 2026Review
- Plant-Derived Exosome-like Nanovesicles for Metabolic Dysfunction-Associated Steatotic Liver Disease.Veterinary sciences · 2026Review
- Curcumin Pretreatment Alleviates Early Mannheimia Haemolytica-Induced Pulmonary Injury in Mice and Is Associated with Changes in Gut Microbial Composition.Microorganisms · 2026Article
- Extracellular Vesicles Derived fromNanomaterials (Basel, Switzerland) · 2026Article
- Past, Present, and Future of Plant-Derived Extracellular Vesicles in Biomedical Applications.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Multi-Dimensional Mechanisms and Druggability Optimization Strategies of Active Ingredients from Traditional Chinese Medicine in the Treatment of Ulcerative Colitis.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Plant-bacteria hybrid nanovesicles for targeted sonodynamic therapy: A microbiome-friendly precision strike againstMaterials today. Bio · 2026Article
- Cargo-driven extracellular vesicles as pharmaceutical nanocarriers: A pharmaceutics-oriented comparison of animal exosomes and plant-derived exosome-like nanoparticles.International journal of pharmaceutics: X · 2026Review
- Chinese bayberry exosome-like nanoparticles attenuate DSS-induced colitis via immunomodulation, barrier restoration, and microbiota remodeling.NPJ science of food · 2026Article
- Plant-Derived Nanovesicles: A Comprehensive Review from Isolation to Clinical Translation-Unlocking Natural Nanocarriers for Biomedical Applications.Biomolecules · 2026Review
- Plant-derived nanovesicles: the intelligent nanoplatforms for therapeutics and drug delivery.Journal of nanobiotechnology · 2026Review
- Trojan horse-inspired smart single-atom nanozyme delivery system for synergistic therapy of inflammatory bowel disease.Acta pharmaceutica Sinica. B · 2026Article
- Oral natural extracellular vesicles for biomedical applications: Advances and clinical perspectives.Journal of advanced research · 2026Review
- Edible Plant-Derived Exosome-like Nanoparticles as Prebiotic Nanocarriers: Gut Microbiota Modulation and Functional Food Potential.Pharmaceutics · 2026Review
- Mechanistic Insights into Plant-Derived Exosomes, Their Cross-Kingdom Effects, and Potential Biomedical Applications in Skin Wounds Repair.Plants (Basel, Switzerland) · 2026Review
- Ayurvedic Medicinal Plants and Plant-Derived Extracellular Vesicles: Current Evidence and Future Perspectives.Nanomaterials (Basel, Switzerland) · 2026Review
- Turmeric-derived exosome-coated ZIF-8 nanoplatform for targeted delivery of TGF-β1 siRNA in the treatment of liver fibrosis.Journal of nanobiotechnology · 2026Article
- Therapeutic Modulation of Inflammatory Signaling via Physalis Peruviana-Derived Exosomes: A Targeted Effect on IKK/NFκB/STAT1.Molecular nutrition & food research · 2026Article
- Novel multifunctional composite cryogel with high-performance and rapid fat-lowering efficacy via the synergy of fat digestion blockage and synthesis inhibition.Bioactive materials · 2026Article
91 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundUlcerative colitis (UC) is an inflammatory bowel disease (IBD) characterized by diffuse inflammation of the colonic mucosa and a relapsing and remitting course. The current therapeutics are only modestly effective and carry risks for unacceptable adverse events, and thus more effective approaches to treat UC is clinically needed.
resultsFor this purpose, turmeric-derived nanoparticles with a specific population (TDNPs 2) were characterized, and their targeting ability and therapeutic effects against colitis were investigated systematically. The hydrodynamic size of TDNPs 2 was around 178 nm, and the zeta potential was negative (- 21.7 mV). Mass spectrometry identified TDNPs 2 containing high levels of lipids and proteins. Notably, curcumin, the bioactive constituent of turmeric, was evidenced in TDNPs 2. In lipopolysaccharide (LPS)-induced acute inflammation, TDNPs 2 showed excellent anti-inflammatory and antioxidant properties. In mice colitis models, we demonstrated that orally administrated of TDNPs 2 could ameliorate mice colitis and accelerate colitis resolution via regulating the expression of the pro-inflammatory cytokines, including TNF-α, IL-6, and IL-1β, and antioxidant gene, HO-1. Results obtained from transgenic mice with NF-κB-RE-Luc indicated that TDNPs 2-mediated inactivation of the NF-κB pathway might partially contribute to the protective effect of these particles against colitis.
conclusionOur results suggest that TDNPs 2 from edible turmeric represent a novel, natural colon-targeting therapeutics that may prevent colitis and promote wound repair in colitis while outperforming artificial nanoparticles in terms of low toxicity and ease of large-scale production.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.